47 results about "Gastrin-releasing peptide" patented technology

The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure:

wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof.

Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided. Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer, methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer.

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N-O-P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

The invention relates to the immunoassay medical field, in particularly provides a chemiluminescence immunoassay test kit and a preparing method thereof for pro gastrin releasing peptide (31-98). Through adopting Biotin-Streptoavidin system coated antibody, the invention can improve antibody coating efficiency, and can improve the sensitivity at the same time. The test kit provides diagnosis of small-cell lung cancer with accurate chemiluminescence test kit which has simple operation and sensitive result detecting, so as to meet the requirements in clinical diagnosis.

This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (AM) or gastrin releasing peptide (GRP) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or blocking antibodies specific for the peptides, are also described, as are pharmaceutical compositions comprising the modulatory agents, and methods for using the modulatory agents to diagnose or treat patients.

The invention discloses a model for predicating lung cancer risks for people suffering from pulmonary nodules among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The model comprises biomarkers, enzyme-labeled antibodies of the biomarkers, a carbonate buffer solution with the pH value being 9.6, a phosphate buffer solution with a pH value being 7.4, a serum protein diluent, a stop solution, a tetramethyl benzidine substrate solution, serum of normal people and positive control serum; the biomarkers are four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens and are combined with CT imageology parameters and other clinical indexes. The model can assist in screening of lung cancer.

The invention provides a targeted nano-microbubble for treating small cell lung cancer, a preparation method and application thereof. Targeted nano-microbubbles include a lipid bimolecular shell and an inert gas wrapped inside the lipid bimolecular shell, and the anti-progastrin releasing peptide monoclonal antibody of small cell lung cancer and paclitaxel are connected to the lipid bimolecular shell, The average particle size of nano-microbubbles is 300-500nm. Preparation method: dipalmitolecithin, distearoylphosphatidylethanolamine, dipalmitophosphatidic acid and paclitaxel were completely dissolved in chloroform by film hydration method to prepare paclitaxel-containing liposomes, which are aimed at anti-progastrocytosis of small cell lung cancer The hormone-releasing peptide monoclonal antibody was opened with mercaptoethylamine, incubated with the liposome above to form a stable thioether bond, and then perfluoropropane gas was passed through, and the anti-monogastric antibody targeting small cell lung cancer was obtained by mechanical vibration. Secretin-releasing peptide monoclonal antibody targeting paclitaxel nanomicrobubbles. The targeted nanometer microbubble can be used in the preparation of medicines for treating small cell lung cancer.

The invention discloses a two-photon fluorescence immunochromatographic kit using a fluorescent dye as a marker and used for quantitative determination of pro-GRP. The two-photon fluorescence immunochromatographic kit provided by the invention realizes fluorescent quantitative detection of pro-GRP, has the advantages of good stability, a wide linear range, good specificity, accurate quantification, easiness and quickness, can simultaneously detect whole blood, serum and plasma samples, and is applicable to all levels of hospitals and family practice.

Methods, and compositions are provided for inhibition of histamine and non-histamine dependent itch signal transmission or scratch behavior. In one aspect, the present invention further comprises administering to the subject an inhibitor of histamine-dependent itch signal transmission. In some cases, the inhibitor of histamine independent itch signal transmission comprises an NK-1 receptor antagonist or the inhibitor of histamine independent itch signal transmission comprises a GRP receptor antagonist. In some cases, the method comprises administering two inhibitors of histamine independent itch signal transmission. For example, the inhibitors of histamine independent itch signal transmission can comprise an NK-1 receptor antagonist and a GRP receptor antagonist. In another embodiment, the invention provides a method of treating itch comprising administering to a subject suffering from itch an NK-1 receptor antagonist, a GRP receptor antagonist.

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure:

wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

A method of treating an inflammatory disease in a subject in need thereof is carried out by administering the subject a gastrin-releasing peptide (GRP) inhibitor in a treatment effective amount. Suitable GRP inhibitors include compounds of the general formula:

and pharmaceutically acceptable salt or prodrugs thereof.

Disclosed is a novel high-sensitive ProGRP measurement method, which is free from problems such as the fluctuations in measurement values and the operational constraints (e.g., the constraints on the handling of a sample). Specifically disclosed is a method for the measurement of a gastrin-releasing peptide precursor and/or a digested product thereof using at least two different antibodies each of which can recognize an epitope represented by the amino acid sequence consisting of amino acid 47 to amino acid 68 of the amino acid sequence set forth in SEQ ID NO:1. The method can detect a ProGRP or a digested product thereof in a refrigerated sample within a shorter period, by using the sample in a smaller amount, and with a higher degree of detective sensitivity, compared with the conventional methods.

The invention relates to a fusion protein which can directionally kill tumor cells. The fusion protein comprises a guiding part composed of gastrin-releasing peptide (GRP) and an effect part composed of cytotoxin, and has a characteristic of directionally reaching and killing tumor cells which overexpress GRP receptors.